NO973685L - Multi-tumor avvikende vekstgener - Google Patents

Multi-tumor avvikende vekstgener

Info

Publication number
NO973685L
NO973685L NO973685A NO973685A NO973685L NO 973685 L NO973685 L NO 973685L NO 973685 A NO973685 A NO 973685A NO 973685 A NO973685 A NO 973685A NO 973685 L NO973685 L NO 973685L
Authority
NO
Norway
Prior art keywords
genes
aberrant growth
growth genes
tumor aberrant
tumor
Prior art date
Application number
NO973685A
Other languages
English (en)
Other versions
NO973685D0 (no
Inventor
Joern Bullderdiek
Willem Jan Marie Van De Ven
Henricus Franscis Schoenmakers
Rafael Mols
Original Assignee
Leuven Res & Dev Vzw
Joern Bullderdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973685(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leuven Res & Dev Vzw, Joern Bullderdiek filed Critical Leuven Res & Dev Vzw
Publication of NO973685D0 publication Critical patent/NO973685D0/no
Publication of NO973685L publication Critical patent/NO973685L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)

Abstract

Foreliggende oppfinnelse vedrører multisvulst-awikende vekstgener (MAG-gener) med nukleotidsekvensen for hvilken som helst kjede av hvilket som helst av elemen- tene av høymobilitetsgruppe-proteingenene eller LIM- proteingenene, også modifiserte versjoner derav. Genet og dets derivater kan anvendes i forskjellige diagnos- tiske og terapeutiske applikasjoner.
NO973685A 1995-02-17 1997-08-11 Multi-tumor avvikende vekstgener NO973685L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95200390 1995-02-17
EP95201951A EP0727487A1 (en) 1995-02-17 1995-07-14 Multiple-tumor aberrant growth genes
PCT/EP1996/000716 WO1996025493A1 (en) 1995-02-17 1996-02-19 Multiple-tumor aberrant growth genes

Publications (2)

Publication Number Publication Date
NO973685D0 NO973685D0 (no) 1997-08-11
NO973685L true NO973685L (no) 1997-10-17

Family

ID=8220025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973685A NO973685L (no) 1995-02-17 1997-08-11 Multi-tumor avvikende vekstgener

Country Status (14)

Country Link
US (3) US6544784B1 (no)
EP (3) EP0727487A1 (no)
JP (4) JPH11500614A (no)
KR (1) KR19980702276A (no)
AT (1) ATE338114T1 (no)
AU (1) AU4879096A (no)
CA (1) CA2213237A1 (no)
CZ (1) CZ247597A3 (no)
DE (2) DE811061T1 (no)
FI (1) FI973354L (no)
HU (1) HUP9800028A3 (no)
NO (1) NO973685L (no)
PL (1) PL321831A1 (no)
WO (1) WO1996025493A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323329B1 (en) 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
WO1998050536A1 (en) * 1997-05-07 1998-11-12 University Of Medicine & Dentistry Of New Jersey Hmgi proteins in tumors and obesity
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
ATE417927T1 (de) 1997-07-30 2009-01-15 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
JP2002513587A (ja) * 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
WO1999057012A2 (de) 1998-05-05 1999-11-11 Elau Elektronik Automations Ag Verpackungsmaschine
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
CA2452202A1 (en) * 2001-06-27 2003-01-09 The Walter And Eliza Hall Institute Of Medical Research Diagnostic methods and agents
JP2005511770A (ja) * 2001-12-19 2005-04-28 アルケド バイオテック ゲーエムベーハー Ｈｍｇｂタンパク質およびｈｍｇｂタンパク質をコードする核酸の使用方法
US20030219742A1 (en) * 2002-03-29 2003-11-27 Sanjay Bhanot Antisense modulation of HMGI-C expression
US20040005601A1 (en) * 2002-04-05 2004-01-08 Adam Siddiqui-Jain Methods for targeting quadruplex DNA
CA2496303A1 (en) * 2002-08-20 2004-03-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for regulating transcription by targeting quadruplex dna
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
JP5366039B2 (ja) * 2008-03-18 2013-12-11 株式会社常光 悪性腫瘍の予想、診断のための方法および組成物
US20100297649A1 (en) * 2009-04-22 2010-11-25 Oliveira Andre M Methods and materials for detecting gene amplification
WO2013050540A1 (en) 2011-10-05 2013-04-11 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
US20180127831A1 (en) * 2015-05-21 2018-05-10 Université de Montréal Prognostic markers of acute myeloid leukemia survival

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0498827B1 (en) * 1989-11-02 2001-08-01 DictyTech Pty Limited Improved plasmid vectors for cellular slime moulds of the genus dictyostelium
US5756307A (en) * 1991-09-20 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Sequence of human dopamine transporter cDNA
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer

Also Published As

Publication number Publication date
EP0811061A1 (en) 1997-12-10
JP2007082549A (ja) 2007-04-05
JP2008099698A (ja) 2008-05-01
HUP9800028A2 (hu) 1998-04-28
EP0727487A1 (en) 1996-08-21
FI973354A7 (fi) 1997-10-16
WO1996025493A1 (en) 1996-08-22
DE69636495D1 (de) 2006-10-12
HUP9800028A3 (en) 2001-02-28
EP0811061B1 (en) 2006-08-30
ATE338114T1 (de) 2006-09-15
JPH11500614A (ja) 1999-01-19
CZ247597A3 (cs) 1998-07-15
DE69636495T2 (de) 2007-05-24
US6544784B1 (en) 2003-04-08
US20110318834A1 (en) 2011-12-29
EP1762619A3 (en) 2007-05-09
JP2009254378A (ja) 2009-11-05
KR19980702276A (ko) 1998-07-15
EP1762619B1 (en) 2013-06-26
PL321831A1 (en) 1997-12-22
FI973354A0 (fi) 1997-08-15
AU4879096A (en) 1996-09-04
EP1762619A2 (en) 2007-03-14
US20030190285A1 (en) 2003-10-09
DE811061T1 (de) 2002-10-17
CA2213237A1 (en) 1996-08-22
FI973354L (fi) 1997-10-16
EP0811061B2 (en) 2010-07-21
NO973685D0 (no) 1997-08-11

Similar Documents

Publication Publication Date Title
NO973685L (no) Multi-tumor avvikende vekstgener
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
AU7489687A (en) Translation of mrna
NO872757D0 (no) Alkynylaminonukleotider og fremgangsmaate for fremstilling av disse.
DK0759927T3 (da) Pteridinnucleotidanaloger som fluorescerende DNA prober
ATE366806T1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
EP1170992A4 (en) CLEANED AND ISOLATED GENES OF THE -I (PIWI) FAMILY, YOUR GENE PRODUCTS; AND METHOD FOR USE
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
MXPA03006984A (es) Secuencia de nucleotidos que median la fertilidad masculina y metodo de uso de la misma.
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE69816467D1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
HUP9802681A1 (hu) Onkogénnel vagy vírussal szabályozott expressziós rendszerek
MX9806041A (es) Proteina purificada sr-p70.
ATE225805T1 (de) Hundecoronavirus s gen und verwendung davon
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
ATE278781T1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
ATE205538T1 (de) Genregulatorische sequenzen von cd4, welche spezifisch in reifen t-zellen exprimiert werden
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
DE69616288D1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application